Timothy E. Ritter

2.3k total citations · 1 hit paper
38 papers, 442 citations indexed

About

Timothy E. Ritter is a scholar working on Genetics, Epidemiology and Immunology. According to data from OpenAlex, Timothy E. Ritter has authored 38 papers receiving a total of 442 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Genetics, 23 papers in Epidemiology and 12 papers in Immunology. Recurrent topics in Timothy E. Ritter's work include Inflammatory Bowel Disease (26 papers), Microscopic Colitis (20 papers) and Biosimilars and Bioanalytical Methods (7 papers). Timothy E. Ritter is often cited by papers focused on Inflammatory Bowel Disease (26 papers), Microscopic Colitis (20 papers) and Biosimilars and Bioanalytical Methods (7 papers). Timothy E. Ritter collaborates with scholars based in United States, Italy and Belgium. Timothy E. Ritter's co-authors include Brian G. Feagan, Silvio Danese, Bruce E. Sands, Douglas C. Wolf, William J. Sandborn, Laurent Peyrin‐Biroulet, Marla C. Dubinsky, Stefan Schreiber, Séverine Vermeire and Andrés Yarur and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Gastroenterology.

In The Last Decade

Timothy E. Ritter

34 papers receiving 433 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies

2023 190 citations William J. Sandborn, Séverine Vermeire et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Timothy E. Ritter United States	11	279	215	110	89	56	38	442
B G Feagan Canada	7	369 1.3×	262 1.2×	90 0.8×	200 2.2×	43 0.8×	28	512
Aušrinė Barakauskienė Lithuania	9	335 1.2×	314 1.5×	199 1.8×	101 1.1×	53 0.9×	15	557
Takahiko Toyonaga Japan	13	253 0.9×	230 1.1×	104 0.9×	70 0.8×	53 0.9×	30	438
Maria Weidinger Germany	9	272 1.0×	162 0.8×	80 0.7×	138 1.6×	36 0.6×	15	408
Ivan Ferkolj Slovenia	11	276 1.0×	193 0.9×	120 1.1×	111 1.2×	28 0.5×	23	416
Gaurav Syal United States	11	289 1.0×	247 1.1×	172 1.6×	50 0.6×	37 0.7×	50	446
Carmen Stefănescu France	10	410 1.5×	307 1.4×	188 1.7×	73 0.8×	90 1.6×	14	484
Leonardo Salese United States	13	501 1.8×	328 1.5×	181 1.6×	75 0.8×	34 0.6×	56	606
Javaid Subhani United Kingdom	6	305 1.1×	211 1.0×	101 0.9×	122 1.4×	34 0.6×	12	466
Renáta Bor Hungary	12	223 0.8×	187 0.9×	169 1.5×	129 1.4×	33 0.6×	74	468

Countries citing papers authored by Timothy E. Ritter

Since Specialization

Citations

This map shows the geographic impact of Timothy E. Ritter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Timothy E. Ritter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Timothy E. Ritter more than expected).

Fields of papers citing papers by Timothy E. Ritter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Timothy E. Ritter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Timothy E. Ritter. The network helps show where Timothy E. Ritter may publish in the future.

Co-authorship network of co-authors of Timothy E. Ritter

This figure shows the co-authorship network connecting the top 25 collaborators of Timothy E. Ritter. A scholar is included among the top collaborators of Timothy E. Ritter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Timothy E. Ritter. Timothy E. Ritter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Steinwurz, Flávio, Silvio Danese, Tadakazu Hisamatsu, et al.. (2025). Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn’s Disease: Results From the Phase 3 GRAVITI Study. Gastroenterology. 169(2). 308–325. 12 indexed citations

Lee, Scott D., Keith A. Betts, Ella X. Du, et al.. (2024). Real-World Patterns and Economic Burden Associated With Treatment Failure With Advanced Therapies in Patients With Moderate-to-Severe Ulcerative Colitis. Crohn s & Colitis 360. 6(2). otae026–otae026. 1 indexed citations

Nakase, Hiroshi, Silvio Danese, Walter Reinisch, et al.. (2024). Mediators of Filgotinib Treatment Effects in Ulcerative Colitis: Exploring Circulating Biomarkers in the Phase 2b/3 SELECTION Study. Inflammatory Bowel Diseases. 31(4). 1095–1108. 1 indexed citations

Vermeire, Séverine, Stefan Schreiber, David T. Rubin, et al.. (2024). Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial. The Lancet. Gastroenterology & hepatology. 10(2). 138–153. 2 indexed citations

Vermeire, Séverine, Bruce E. Sands, Laurent Peyrin‐Biroulet, et al.. (2024). Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials. Journal of Crohn s and Colitis. 18(11). 1780–1794. 5 indexed citations

Sands, Bruce E., Brian G. Feagan, Laurent Peyrin‐Biroulet, et al.. (2024). Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis. New England Journal of Medicine. 391(12). 1119–1129. 23 indexed citations

Sands, Bruce E., Laurent Peyrin‐Biroulet, Silvio Danese, et al.. (2023). 477a A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMISUC, COHORT 1. Gastroenterology. 164(6). S–1570. 1 indexed citations

Herfarth, Hans, Anita Afzali, Monika Fischer, et al.. (2023). Clinical Long-Term Outcomes of Patient-Reported Outcomes in the Prospective Real-World Tofacitinib Response in Ulcerative Colitis Registry. Clinical and Translational Gastroenterology. 15(3). e00669–e00669. 1 indexed citations

Reinisch, Walter, Wayne J.G. Hellstrom, Radboud J. E. M. Dolhain, et al.. (2023). Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studies. Annals of the Rheumatic Diseases. 82(8). 1049–1058. 20 indexed citations

10.

Sandborn, William J., Séverine Vermeire, Laurent Peyrin‐Biroulet, et al.. (2023). Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. The Lancet. 401(10383). 1159–1171. 190 indexed citations breakdown →

11.

Long, Millie D., Anita Afzali, Monika Fischer, et al.. (2022). Tofacitinib Response in Ulcerative Colitis (TOUR): Early Response After Initiation of Tofacitinib Therapy in a Real-world Setting. Inflammatory Bowel Diseases. 29(4). 570–578. 18 indexed citations

12.

Hellstrom, Wayne J.G., Radboud J. E. M. Dolhain, Timothy E. Ritter, et al.. (2022). MANTA and MANTA-RAy: Rationale and Design of Trials Evaluating Effects of Filgotinib on Semen Parameters in Patients with Inflammatory Diseases. Advances in Therapy. 39(7). 3403–3422. 29 indexed citations

13.

Hengel, Richard L., et al.. (2022). Recurrent Clostridioides difficile infection worsens anxiety-related patient-reported quality of life. Journal of Patient-Reported Outcomes. 6(1). 49–49. 10 indexed citations

14.

Papamichael, Konstantinos, Vipul Jairath, Guangyong Zou, et al.. (2022). Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn’s disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial). BMJ Open. 12(4). e057656–e057656. 20 indexed citations

15.

Danese, Silvio, Marc Ferrante, Brian G. Feagan, et al.. (2022). Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION Trial. The American Journal of Gastroenterology. 118(1). 138–147. 18 indexed citations

16.

Sands, B E, Axel Dignaß, Peter M. Irving, et al.. (2022). P316 Ozanimod is an efficacious oral therapy after, 5-ASA failure in immunomodulator- and biologic-naive patients with ulcerative colitis: post hoc analysis from True North. Journal of Crohn s and Colitis. 16(Supplement_1). i339–i340. 3 indexed citations

17.

Danese, Silvio, Toshifumi Hibi∥, Timothy E. Ritter, et al.. (2021). OP37 Rapidity of symptom improvements during filgotinib induction therapy in patients with Ulcerative Colitis: Post hoc analysis of the phase 2b/3 SELECTION study. Journal of Crohn s and Colitis. 15(Supplement_1). S034–S035. 1 indexed citations

18.

Hengel, Richard L., et al.. (2020). Real-world Experience of Bezlotoxumab for Prevention of Clostridioides difficile Infection: A Retrospective Multicenter Cohort Study. Open Forum Infectious Diseases. 7(4). ofaa097–ofaa097. 32 indexed citations

19.

Garey, Kevin W., et al.. (2020). 787. Evaluation of Clostridioides difficile Environmental Contamination Surrounding C. difficile Patients vs. non-C. difficile Patients in Outpatient Infusion Centers. Open Forum Infectious Diseases. 7(Supplement_1). S438–S438.

20.

Ritter, Timothy E., et al.. (2018). Failure of Vedolizumab as First-Line Biologic Does Not Decrease Response Rates of Second-Line Therapy. The American Journal of Gastroenterology. 113(Supplement). S382–S383. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact